Evolving Therapies in Relapsed and Refractory Hodgkin Lymphoma by Sulada Pukiat & Francisco J. Hernandez-Ilizaliturri
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
7 
Evolving Therapies in Relapsed 
 and Refractory Hodgkin Lymphoma 
Sulada Pukiat and Francisco J. Hernandez-Ilizaliturri* 
Departments of Medical Oncology and Immunology, 
Roswell Park Cancer Institute, 
Buffalo, NY, 
USA 
1. Introduction 
Approximately 20% of Hodgkin Lymphoma (HL) patients do not achieve a durable 
remission or fail to respond to front-line chemotherapy. Despite the attempt to improve 
clinical outcomes by using the risk adaptive therapy, a significant number of patients die as 
a results of relapsed/refractory (rel/ref) disease.1 Advances in understanding the etiology 
and molecular biology of HL are leading the development of novel therapeutic strategies 
that could be applied to improve clinical outcome of rel/ref HL patients. The pathologic 
features of HL reflect a defect in immune responses resulting from various cytokines and 
chemokines secreted partially by Hodgkin Reed-Sternberg (HRS) cells. HRS cells are unique 
in the way that they lost typical B cell gene expression pattern but retain the expression of 
surface molecules involving in antigen presentation (tumor necrosis factor receptor (CD30, 
CD40), CD80, MHC class II, and CD86). Aberration of Notch signaling pathway may 
contribute to their reprogramming.2,3 Multiple genetic lesions, deregulated signaling 
pathway and transcription factors play important role in pathogenesis of HL including 
constitutive activation of nuclear factor kappa B (NFκB) and the Janus kinase-signal 
transducer and activator of transcription (JAK-STAT) signaling pathway.4-6 Moreover, the 
role of the microenvironment in HL has been increasingly recognized. The majority of the 
cell population in HL-affected tissue is composition of the inflammatory cellular infiltrate, 
not the HRS cells that represents only small population (<1%). Understanding the complex 
relationship between the HRS cells and the microenvironment and chemokines milieu 
involved in its formation is crucial for the development of new therapeutic strategies. 
In addition, Epstein Barr Virus (EBV) infection may plays a role in the pathogenesis of HL 
since it can influence the expression of certain chemokines (i.e. CXCL9, CXCL10, CCL3, and 
CCL5) that are highly expressed in HRS cells and the EBV gene encoding the latent 
membrane protein 1 (LMP1) can mimic constitutively active TNF receptor (via a 
CD40/CD40L interaction) and promote IκB turnover leading to activation of NFκB and 
downstream signaling events.7 Ongoing efforts are focused in developing adaptive or 
adoptive immune therapies targeting EVB related proteins in rel/ref HL patients.  
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This chapter will provide an overview of the emerging therapeutic strategies for patients 
with relapsed and refractory HL (rel/ref HL) that had failed standard front line therapy, 
salvage chemotherapy and high-dose chemotherapy and autologous stem cell support 
(HDC-ASCS).  
2. Systemic chemotherapy 
Salvage systemic chemotherapy is often used in patients with rel/ref HL failing HDC-ASCS. 
Response rates are modest and response duration is usually short. Participation in clinical 
trials evaluating novel therapeutic approaches is strongly recommended. On the other hand, 
two chemotherapy agents had proven anti-tumor activity in highly refractory HL patients: 
gemcitabine and bendamustine.  
Gemcitabine had been studied in the rel/ref HL either as single agent or combination 
therapy (i.e. with Vinorelbine).8,9 Favorable toxicity profile and significant clinical anti-
tumor activity were observed in heavily pre-treated HL patients, with overall response rates 
(ORR) up to 70% when used in combination regimens.10,11 On the other hand, the duration 
of response is limited stressing the need to develop novel therapeutic strategies or to use 
this agent as a bridge rel/ref HL patient into more definitive treatments (i.e. allogeneic bone 
marrow transplant or other cellular-based therapies).  
Bendamustine hydrochloride is a bifunctional mechlorethamine derivative with alkylating 
and antimetabolite properties. The exact antitumor mechanism is unknown though it 
appears to crosslink macromolecules resulting in DNA damage and subsequently apoptosis. 
It may also inhibit mitotic checkpoints and induce mitotic catastrophe. Bendamustine 
showed marked antiproliferative and proapoptotic effects on HL cell lines.12 Moskowitz et al 
reported the activity of single agent bendamustine in rel/ref HL that previously failed 
HDC-ASCT, allogeneic stem cell transplantation (AlloSCT) or ineligible for transplant.13 In 
this phase II clinical trial, bendamustine was administered at a dose of 120 mg/m2 for two 
consecutive days, every 28 days, for up to maximum of 6 cycles. Of evaluable 16 patients, 
there were 6 complete responses (CRs) (38%) and 6 partial responses (PRs) (38%) for an ORR 
of 75%. Further studies of both single agent bendamustine and in combination with other 
chemotherapy are warranted in rel/ref HL patients.   
3. Passive immunotherapy targeting the tumor microenvironment and/or HRS 
cells (Table 1) 
3.1 CD80 (B7-1) 
Immunohistochemical analysis has shown strong expression of CD80 on HRS cells, antigen 
presenting cells (APCs), T-cells and activated B-cells but not on resting B-cells and plasma 
cells and is absolutely absent on CD34+ cells, making CD80 an excellent target in HL. 
Preclinical data demonstrated that an anti-B7-1 immunotoxin had significant anti-tumor 
activity in HL-cell lines and minimal toxicity to CD34+ hematopoietic stem cell.14,15 
Galiximab is a primatized IgG1 monoclonal antibody, which binds to CD80 with high 
affinity and induces cell death via antibody-dependent cell-mediated cytotoxicity (ADCC). 
Smith et al studied the clinical activity of single agent Galiximab in patients with rel/ref HL 
not eligible for or had failed HDC-ASCT/AlloSCT.16 Galiximab was administered at a dose 
of 500 mg/m2 weekly for 4 weeks followed by 500 mg/m2 every 4 weeks until disease  
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Author Agent 
Study 
Design 
(Phase) 
Patient 
population 
Clinical 
Activity 
Median 
Duration of 
Response 
Adverse Reaction 
Smith et al10 Galiximab II 
Rel/ref HL 
(N=30) 
ORR 6.9%; 1 
CR, 1 PR 
2 responders 
progressed 
after 7.5 and 
3 mo. 
Gr 3-4 hypo-
phosphatemia, 
elevated SGOT/ 
SGPT, infection 
Freedman et 
al20 
Lucatumuma
b 
Ia/II 
Rel/ref HL 
(N=28) or 
NHL (N=31) 
Ia N=10: 
ORR 10%; 1 
PR 
II N=18: 
ORR 17%; 3 
PR 
NR 
Gr 3-4 
asymptomatic/ 
reversible elevated 
amylase/lipase, 
SGOT/SGPT 
Younes et 
al23 
Rituximab N/A 
Rel/ref HL 
(N=22) 
ORR 22%; 1 
CR, 4 PR 
DOR 8.7 
mo. (3.3+-
14.9 mo.) 
NR 
Corazzelli et 
al26 
Rituximab + 
Gemcitabine, 
Ifosfamide, 
Oxaliplatin 
(R+GIFOX) 
N/A 
Rel/ref HL 
(N=21) 
ORR 86%; 
16 CR, 2 PR 
NR 
Gr 4 TCP, 
infection 
Oki et al27 
Rituximab + 
Gemcitabine 
II 
Rel/ref HL 
(N=33) 
ORR 48%; 5 
CR, 11 PR 
FFS 2.7 mo. 
Gr 3-4 
neutropenia, TCP 
Ekstrand et 
al29 
Rituximab II 
CD20+ newly 
diagnosed and 
rel/ref NLPHL 
(N=22) 
ORR 100%; 
10 CR, 12 
PR 
FFP 10.2 
mo. 
Infusion related 
reaction, Gr 1 
hematologic 
toxicities, No Gr 
3-4 toxicity 
Rehwald et 
al30 
Rituximab II 
NLPHL or 
CD20+ 
relapsed cHL 
(N=14) 
ORR 86%; 8 
CR, 4 PR 
Not reach at 
20+ mo. 
Infusion related 
reaction, Gr 1-2 
chill, fever, rhinitis, 
nausea, pruritus, 
leucopenia, 
dizziness 
Eichenauer 
et al31 
Rituximab II 
Newly 
diagnosed 
stage IA 
NLPHL 
(N=28) 
ORR 100%; 
24 CR, 4 PR 
NR No Gr 3-4 toxicity 
Schulz et 
al32 
Rituximab II 
Rel/ref 
NLPHL 
(N=15); cHL 
(N=4) 
NLPHL: 
ORR 94%; 8 
CR, 6 PR 
HL: 3 CR 
TTP 33 mo. 
OS not 
reached 
NR 
HL = Hodgkin Lymphoma; Rel/ref = relapsed/refractory; ORR = overall response rate; CR = complete 
response; PR = partial response; Gr = grade; NLPHL = Nodular lymphocyte predominant Hodgkin 
lymphoma; TTP = time to progression; FFP = freedom from progression; OS = overall survival;  
NR = Not reported; TCP = thrombocytopenia 
Table 1. Monoclonal antibodies targeting HRS cells or accessory cells in relapsed/refractory 
Hodgkin Lymphoma. 
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progression or unacceptable toxicity. The results were disappointing with ORR of only 
6.9% and very short median time to progression (TTP) of 1.6 month. The authors 
concluded that single agent galiximab seems to have minimal activity in heavily 
pretreated rel/ref HL. 
3.2 CD40 
CD40 is a member of TNFR family (TNFRSF5) that is constantly expressed in HRS cells. In 
addition, CD40+ HRS cells are surrounded by CD40L-expressing T-cell lymphocytes. The 
CD40/CD40L interaction contributes to the pathobiology of HL possibly by NFκB activation 
and increased autocrine growth factor CCL5 resulting in inhibition of apoptosis, increased 
proliferation and microenvironment formation.17-19 
Lucatumumab is a monoclonal antibody targeting the transmembrane receptor CD40. The 
safety and clinical activity of lucatumumab (HCD122) was evaluated in both NHL and HL 
patients who have progressed after at least two previous therapies [NCT00670592].20 
Patients received lucatumumab at a dose of 3 or 4 or 6 mg/kg intravenous weekly for 4 
weeks followed by a 4-weeks rest period. The maximum tolerated dose (MTD) and dose 
limiting toxicity (DLT) were 4 mg/kg and 6 mg/kg, respectively. DLTs were consisted of 
clinically asymptomatic and reversible grade 3-4 elevation of amylase/lipase or transminase 
enzymes. For rel/ref HL patients, three of eighteen (17%) patients in phase II study 
component achieved a PR.  
3.3 CD52 
CD52 is highly expressed in surrounding reactive B-cells, T-cells and monocytes, although 
not on HRS cells itself. Depleting CD52+ accessory cells, which appear to provide survival 
signals to HRS cells, may have therapeutic value. Alemtuzumab is a humanized monoclonal 
antibody directed against CD52 resulting in cell lysis via antibody dependent cellular-
mediated cytotoxicity. A phase II study addressing the clinical efficacy of alemtuzumab in 
rel/ref HL was unfortunately terminated due to slow accrual [NCT00129753].21 Another 
phase II study focusing on the clinical outcome in rel/ref DLBCL and HL treated with 
alemtuzumab in combination with dose-adjusted EPOCH-Rituximab is currently enrolling 
patients [NCT01030900].22 
3.4 CD20 
A pilot study evaluating rituximab monotherapy in rel/ref HL has shown that depletion of 
B lymphocytes may has therapeutic potential.23 The rationale of using rituximab in classical 
HL (cHL) is based on several laboratory and clinical observations: HRS stem cells express 
CD20 even though HRS cells infrequently express CD20, elimination of CD20+ B 
lymphocytes supporting HRS cells may deprive survival signals and improve immune 
response against HRS cell.24,25 Studies of evaluating the addition of rituximab to 
conventional chemotherapy in patients with rel/ref cHL demonstrated promising 
results.26,27 Copeland et al showed significant improvement of 5-year event free survival 
(EFS) in patients with newly diagnosed advanced stage cHL treated rituximab plus ABVD 
compared to historical data of patients treated with ABVD from the same institute.28 
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Targeting CD20 in patients with lymphocyte predominant HL (LPHL, had show to be an 
effective therapeutic strategy in contrast to other subtypes of HL. The efficacy of rituximab 
in LPHL was documented in several phase II studies with an ORR up to 100% in both 
relapsed and newly diagnosed patients.29-32 Zojer et al and Schnell et al reported 2 cases of 
rel/ref HL patients treated with radiolabeled anti-CD20 monoclonal antibody, Yttrium-90 
ibritumomab tiuxetan.33,34 One patient had LPHL and another patient had cHL (lymphocyte 
rich) both achieved a complete remission following radioimmunotherapy (RIT). A Phase 
I/II study of safety and efficacy of I131 tositumomab rel/ref CD20+ cHL is currently 
enrolling patients [NCT00484874].35  
4. Signaling pathway targets on HRS cells 
4.1 CD30 signaling (Table 2) 
CD30, a member of tumor necrosis factor receptor family (TNFR super family 8) involved in 
the activation of the canonical NFκB pathway and provides tumor cell survival signaling. 
CD30 is express in almost 100% of the HRS cells and serve as an attractive target of 
immunotherapy for cHL.36,37 Borchmann et al had summarized the upsides and downsides 
of immunotherapy in HL.38 Immunotoxins (ITs) containing ricin A, a ribosome inactivating 
protein, linked with surface marker CD30 as well as other ITs had shown disappointing 
clinical results with regard to response and toxicity in HL. Bi-specific constructs of 
monoclonal antibodies or molecules (BSMs) targeting CD30 and CD16 (NK cells) or CD64 
(monocytes) were though well tolerated and showed some objective responses, production 
of BSMs is very expensive and time consuming. Low dose radioimmunotherapy (RIT), I-131 
labeled anti-CD30 antibofy (131I-Ki-4) used in phase I trial in patients with relapsed HL 
showed some clinical activity with limitation to hematotoxicity particularly 
thrombocytopenia.39 Better choice of radionuclides and the carriers would be necessary to  
 
Author Agent 
Study 
Design 
(Phase) 
Patient 
population 
Clinical 
Activity 
Median 
Duration of 
Response 
Adverse Reaction 
Ansell et 
al41 
Iratumumab 
MDX-060 
Phase 
I/II 
Rel/ref HL 
(N=63) 
4 responses; 
2 CR, 2 PR 
DOR 4 mo. 
Gr 3 elevation of 
transaminase enzyme, 
epitaxis, anemia; gr3-4 
dyspnea, cardiac 
temponade, ARDS 
Younes et 
al43 
Brentuximab 
vedotin 
I 
Rel CD30+ 
lymphomas 
(N=45; 
HL=43) 
ORR 40%; 
CR 27%, PR 
13% (for 
HL) 
DOR 9.7+ 
mo. 
PFS 5.9 mo. 
Peripheral 
neuropathy 
Chen et 
al44 
Brentuximab 
vedotin 
II 
Rel/ref HL 
(N=102) 
ORR 75%; 
CR 34% 
DOR not 
reach (for 
CR pts) 
Peripheral 
neuropathy, 
neutropenia, TCP, 
anemia 
HL = Hodgkin Lymphoma; Rel/ref = relapsed/refractory; ORR = overall response rate; CR = complete 
response; PR = partial response; Gr = grade; NLPHL = Nodular lymphocyte predominant Hodgkin 
lymphoma; DOR = duration of response; PFS = progression free survival 
Table 2. Selected Clinical studies targeting CD30 in relapsed/refractory Hodgkin Lymphoma. 
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further development of this approach. Preclinical study targeting CD30 demonstrated 
significant anti-tumor activity.40 Initial clinical studies evaluated naked antibodies targeting 
CD30 (MDX-030 and SGN-30) in patients with rel/ref HL. Both antibodies failed to 
demonstrate anti-tumor activity and in some cases accelerated tumor growth was observed 
upon CD30 binding by MDX-060.41   
Previously unknown factors influenced the negative results observed in such trials such as 
1) the agonist effects of the antibodies initially tested, 2) the modulation of CD30 in HRS 
cells (i.e. antigen shedding and/or internalization), and/or 3) impaired immune effector 
function in heavily pre-treated patients with HL. Two therapeutic approaches (i.e. 
development of drug conjugates or antibody re-engineering) had been explored clinically 
with significant improvement in clinical activity.  
SGN-35 (brentuximab vedotin) is a drug conjugated designed to improve the clinical activity 
of SGN-30 in lymphomas. Brentuximab vedotin (SGN-35) is a antibody-drug conjugate 
containing the anti-tubulin agent, monomethylauristatin E (MMAE) linked to antiCD30 
monoclonal antibody to enhance antitumor activity.42  
Younes et al reported encouraging results in a phase I study of brentuximab vedotin in 
patients with relapsed CD30+ lymphomas.43 Most of patients in the study had rel/ref HL 
(42/45), were heavily pre-treated (median number of previous regimens was 3), and almost 
75% had previous HDC-ASCT. Seventeen patients had objective response including 11 CRs. 
Fifty percent (6/12) of patients who received maximum tolerating dose (MTD) 
(1.8mg/kg/dose) had objective responses. 
Subsequently, a pivotal phase II of brentuximab vedotin in patients with rel/ref HL 
reported similar results.44 All patients had failed HDC-ASCT and had median of 3.5 prior 
treatments. The ORR was 75% (76/102) with 34% of the patients achieving a CR (35/102). 
Currently, a randomized, double blind, placebo-controlled phase III study is evaluating 
SGN-35 versus placebo in patients at high-risk for residual disease after HDC-ASCT is 
ongoing [NCT01100502].45 Brentuximab vedotin in combination with standard 
chemotherapy (ABVD) was now being evaluated in patients with newly diagnosed 
Hodgkin lymphoma stage IIA-IV [NCT01060904].46 SGN-35 received fast track designation 
from the U.S. Food and Drug Administration (FDA) for the treatment of HL in 2009. 
5. Downstream signaling targets (Table 3) 
5.1 NFκB activity 
As previously noted, constitutive activation of NFκB is one of the most important events in 
pathogenesis of HL and the result of multiple mechanisms. Downstream signaling of TNF 
receptors, expression of the EBV LMP1, and/or mutation of IκB gene have been described as 
the cause of constitutive NFκB activation. Inhibition of NFκB has been an area of drug 
development for the treatment of multiple hematological malignancies including HL. Pre-
clinical data demonstrated that the proteasome inhibitor, PS-341 (Bortezomib) affects tumor 
cell proliferation and survival via inhibiting NFkB pathway, which is constitutively 
activated in HRS cells. As a result, bortezomib was evaluated in patients with rel/ref HL. 
The Cancer and Leukemia Group B (CALGB) conducted a phase II clinical trials (CALGB 
50206) evaluating bortezomib monotherapy in rel/ref HL. Disappointingly, no clinical 
www.intechopen.com
 
Evolving Therapies in Relapsed and Refractory Hodgkin Lymphoma 185 
activity was observed in treated patients.47 The lack of anti-tumor activity of bortezomib in 
rel/ref HL was confirmed by two subsequent studies reported by Younes et al and Trelle et 
al.48,49 More recent studies that evaluated bortezomib in combination with conventional 
chemotherapy showed mix results.50,51 
Author Agent 
Study 
Design 
(Phase) 
Patient 
population 
Clinical 
Activity 
Median 
Duration 
of 
Response 
Adverse 
Reaction 
Blum et al47 Bortezomib II 
Rel/ref HL 
(N=30) 
9 SD 
PFS 1.4 
mo. 
OS 14.8 
mo. 
Gr 3-4 TCP 
Youne et al48 Bortezomib N/A 
Rel/ref HL 
(N=14) 
1 PR NR 
Gr 3 TCP, 
dyspnea and 
neutropenic 
fever 
Trelle et al49 
Bortezomib + 
Dexamethasone 
II 
Rel HL 
(N=12) 
No response NR TCP 
Mendler et 
al50 
Bortezomib + 
Gemcitabine 
N/A 
Rel HL 
(N=18) 
ORR 22% NR 
Gr 3 elevation of 
transaminase 
enzyme 
Fanale et al51 
Bortezomib + 
ICE 
I 
Rel/ref HL 
(N=13) 
CR 33%; 9 
Response (8/9 
underwent 
HDC-ASCS) 
NR 
Gr 4 TCP 35%, 
Gr 4 
neutropenia 
18% 
Kirschbaum 
et al54 
Vorinostat II 
Rel/ref HL 
(N=25) 
ORR 4%; 1 
PR 
PFS 4.8 
mo. 
Gr 4 anemia, 
lymphopenia, 
and Gr 3 TCP 
Younes et 
al57 
Mocetinostat II 
Rel/ref HL, 
(N=51) 
110 mg: ORR 
35%; 2 CR, 6 
PR 
85 mg: ORR 
21%; 6 PR 
NR 
Gr 3 TCP, 
fatigue, 
neutropenia, 
non-fatal 
pericardial 
effusion 
Dickinson et 
al56 
Panobinostat IA/II 
Hematologic 
malignancies 
(N=128; 
HL=23 with 
13 evaluable 
pts) 
PR by CT 
38%; PR by 
PET 58% 
NR 
TCP, 
neutropenia, 
febrile 
neutropenia, 
fatigue, anemia 
Sureda et 
al63 
Panobinostat II 
Rel/ref HL 
after ASCT 
(N=129) 
ORR 27%; 5 
CR, 30 PR 
PFS 6.1 
mo. 
Gr 1-2 anemia, 
N/V/D, gr 3-4 
TCP, aneima, 
neutropenia 
Younes et 
al68 
Entinostat II 
Rel/ref HL 
(N=23) 
Disease 
control rate 
(CR+PR+SD) 
65% 
NR 
Gr 1-2 GI 
causalities, 
fatique, 
pyrexia,; gr 3-4 
TCP, anemia, 
neutropenia 
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Author Agent 
Study 
Design 
(Phase) 
Patient 
population 
Clinical 
Activity 
Median 
Duration 
of 
Response 
Adverse 
Reaction 
Viviani et 
al70 
Givinostat II 
Rel/ref HL 
(N=15; 13 
evaluable 
pts) 
7 SD (54%) N 
Gr 1 leukopenia, 
1 diarrhea/ 
abdominal pain; 
Gr 2 TCP; 20% 
had QTc 
prolongation 
Carlo-Stella 
et al71 
Givinostat + 
Meclorethamine 
II 
Rel/ref HL 
(N= 35) 
ORR 38%; CR 
15%. PR 23% 
OS 28 mo. 
TTP 3 mo. 
Gr 1-2 nausea 
and fatigue; gr 
3-4 TCP, anemia 
neutropenia 
Johnston et 
al75 
Everolimus II 
Rel/ref HL 
(N=19) 
ORR 47%; 1 
CR, 8 PR 
TTP 7.2 
mo. 
Gr ≥3 
pulmonary 
toxicity (4 pts) 
HL = Hodgkin Lymphoma; Rel/ref = relapsed/refractory; ORR = overall response rate; CR = complete 
response; PR = partial response; Gr = grade; TCP = thrombocytopenia; TTP= time to progression;  
PFS = progression free survival; OS = overall survival; HDC-ASCS = high dose chemotherapy and 
autologous stem cell support; NR = Not reported 
Table 3. Selected clinical studies evaluating target specific agents in relapsed/refractory 
Hodgkin lymphoma. 
More potent and/or irreversible proteasome inhibitors (i.e. carfilzomib, MLN2238) had 
demonstrated high efficacy in rel/ref multiple myeloma and now are being evaluated in 
other hematologic malignancies.52 However, their clinical activity in HL remains unknown. 
5.2 Deacetylation of histone and other cellular proteins in HL biology: The therapeutic 
role of deacetylase inhibitors (DACi) 
Gene expression profiling studies had demonstrated that HL is characterized by the 
silencing of key regulatory genes involved in B-cell maturation (i.e. CD79a, CD19, CD20, 
etc). In general gene expression is a tightly regulated process that is influenced by the 1) 
DNA/mRNA sequence, 2) expression/activity of transcription factors, 3) epigenetics 
(including the DNA, chromatin, and histone modifications); and 4) messenger RNA 
stability. 
Post-transcriptional histone modification plays an important role in regulating gene 
transcription and is mediated by two groups of enzymes: histone acetyltransferase (HATs) 
and histone deacetylase (HDACs). The balance between HATs and HDACs is crucial in 
regulating the expression/function of several proteins involved in cell proliferation, cell 
cycle, apoptosis, angiogenesis, and immune regulation. Altering balance between HATs and 
HDACs had been found to be associated with various malignancies including HL.  
To date, 18 HDACs have been identified in humans. HDACs are grouped in two major 
categories and four classes; zinc-dependent HDACs (Class I, II and IV) and NAD-dependent 
HDACs (Class III). Class I includes HDAC 1, 2, 3, 8, and 11; Class II includes HDAC 4, 5, 6, 
7, 9, and 10; Class III includes homologues of yeast SIRT 1–7, and Class IV, which includes 
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only HDAC 11. As a group, HDAC are known to regulate several key cellular functions 
such cell proliferation, cell cycle, apoptosis, angiogenesis, migration, antigen presentation, 
and/or immune regulation. The activity spectrum of each HDAC is yet to be defined and 
there is overlap between the function of different HDAC regardless of their group or class.  
HATs and HDACs interact also with non-histone proteins such as transcription factors (i.e. 
p53, STAT3, MYC , E2F, NFκB, etc.), -tubulin, and chaperons (heat shock protein-90 
[HSP90]), adding complexity to their cellular functions in normal and malignant cells. Given 
their influence in multiple regulatory pathways, HDACs became an attractive strategy to 
develop novel pharmacologic inhibitors for the treatment of cancer. Several pan- or 
selective-HDAC inhibitors (class I and IV) had been developed. Pre-clinical studies 
demonstrated significant anti-tumor activity in various cancer models including non-
Hodgkin lymphoma and HL. Laboratory experiments suggest that HDAC inhibitors can 
induce cell cycle arrest, apoptosis or autophagy in cancer cell lines and can potentiate the 
anti-tumor activity of chemotherapy agents including proteasome inhibitors. Two HDAC 
inhibitors had been approved for the management of relapsed/refractory cutaneous T-cell 
lymphoma (vorisnostat and romidepsin). A second generation of more potent and selective 
(i.e. less toxic) of HDAC inhibitors (entinostat, panobinostat and MGCD103) had entered 
into clinical studies for patients with relapsed/refractory HL. 
Vorinostat (SAHA), the first FDA approved HDAC inhibitor, is a potent inhibitor of class I 
and II HDAC and was the first of its class agent evaluated in patients with rel/ref HL. At 
the pre-clinical level, vorinostat has anti-proliferative and pro-apoptotic effects on HL cell 
lines by inducing p21 expression and down regulation of Bcl-xL respectively.53 Kirschbaum 
et al presented on behalf of the South Western Oncology Group (SWOG), the results of a 
phase II clinical trial evaluating the safety and efficacy of Vorinostat in refractory/relapsed 
HL.54 A total of 25 patients were treated with vorinostat at 200 mg given orally twice per 
day for 14 days every 21-day cycle. The activity of vorinostat was modest and only one 
patient achieved a partial remission (PR). Adverse events reported were similarly to those 
reported in vorinostat clinical trials in patients with cutaneous T-cell lymphoma (CTCL). 
Preclinical data by Hartlapp et al demonstrated the activity of depsipeptide (romidepsin) in 
cHL cell lines in vitro.55 In addition, the investigators demonstrated that romidepsin several 
cellular events leading to cell cycle arrest and apoptosis in HL cell lines such as and 
increased DNA binding capacity of RelA/p65, PARP-cleavage, decreased transcription of 
anti-apoptotic proteins (eg. XIAP, Bcl-xL), and down-regulation of STAT6. Romidepsin has 
not been formally evaluated in rel/ref HL patients.  
An isotype-selective histone deacetylase inhibitor, mocetinostat (MGCD-0103), inhibits 
class I and class IV and minimal class II HDAC inhibition. A phase II trial of 2 different 
doses (85 mg and 110 mg thrice weekly every 28 days) of mocetinostat in rel/ref HL had 
shown promising results with ORR of 38%.56 The updated results from the same group 
demonstrated activity of single agent mocetinostat in heavily pretreated rel/ref HL with 
clinical responses observed in approximately 35% of patients with slightly better responses 
with 110 mg cohort.57 Of 51 patients, 2 patients (110 mg cohort) achieved complete 
responses and 6 patients each from both cohort achieved partial response. Over eighty 
percent of patients in the study had previously failed HDC-ASCS and more than half of 
patients received four or more previous treatments. Serum thymus and activation-regulated 
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chemokine (TARC) or CCL17 which is highly expressed in HRS cells, decreased in patients 
treated with mocetinostat.58 This findings were similar what had been previously observed 
following in vitro exposure of HL cell lines to vorinostat.53 Together these findings, suggests 
that a decline in serum TARC may be a biomarker to predict clinical response to DAC 
inhibition therapy. Buglio et al found that MGCD0103 induced apoptosis in HL cell lines via 
the induction of TNFǂ expression and that inhibition of NF-κB activation with bortezomib 
resulted in synergistic anti-tumor activity.59  
Bhalla et al observed similar findings with PCI-24781, a phenyl hydroxamic acid-based 
broad spectrum HDAC inhibitor.60 PCI-24781 combined with bortezomib enhances 
apoptosis via reactive oxygen species (ROS), caspase activation (increased cleavage of 
caspase 8 and caspase 9), PARP activation, cell cycle arrest (G0/G1), and upregulation of 
p21 in HL cell lines and several non-Hodgkin lymphoma (Burkitt’s lymphoma, follicular 
lymphoma, and large B-cell lymphoma) cell lines. While the biological interaction between 
bortezomib and multiple DAC inhibitors had been demonstrated in pre-clinical models and 
is been pursued in several clinical studies in multiple myeloma and mantle cell lymphoma 
patients, the limited activity of bortezomib as a single agent had damped the interest for 
pursuing this combination strategy in rel/ref HL patients.  
Panobinostat (LBH-589) is a potent pan-HDAC inhibitor with anti-tumor activity observed 
in pre-clinical studies at nanomolar concentrations. Moreover, pre-clinical studies suggest 
that panobinostat is more potent than vorinostat in lymphoma pre-clinical models. 
Panobinostat was evaluated in phase IA/II study in 128 patients with advanced hematologic 
malignancies including rel/ref HL.56 Patients received 2 schedules of oral administration 
(MWF every week at a dose of 20, 30, 40, 60, 80 mg/dose or MWF every other week at a 
dose of 30, 45, 60, 80 mg/dose). Out of 23 patients with rel/ref HL, 13 patients were 
evaluable for response. Five out of thirteen (38%) patients had PR by CT and 7/12 patients 
(58%) had metabolic PR by PET. The maximum tolerated dose (MTD) was 40 mg/dose 
every week schedule and the principal dose-limiting toxicity (DTL) was thrombocytopenia.  
Younes et al confirmed efficacy of panobinostat in phase II study in patients with rel/ref 
HL.61 Panobinostat was administered at a dose of 40 mg thrice weekly in 21-day cycle until 
disease progression. The update results showed encouraging clinical activity of 
panobinostat with 1 patient achieved CR and 10 pateints achieved PR.62 Moreover, disease 
control rate (CR+PR+SD) was 79%. Panobinostat was well tolerated and reversible 
thrombocytopenia was managed by dose delay or dose reduction. The interim results for 
this phase II study continues to demonstrate encouraging activity of panobinostat.63 The 
final results are currently not available. As previously demonstrated with other DAC 
inhibitors, a decrease in serum TARC levels was observed in panobinostat treated patients 
achieving an objective response (i.e. PR or CR).64  
The safety and efficacy of the oral agent belinostat (PXD-101) was evaluated in patients 
with rel/ref NHL or cHL by Zain et al.65 Tumor size reduction found in 1/3 of patients with 
HL using the recommended dose-schedule for patients with solid tumors (750 mg daily, D1-
14 every 21days). 
Entinostat (SNDX-275) is a class I isotype-selective HDAC inhibitor with longer half-life. 
Pre-clinical data from Khaskhely et al demonstrated in vitro activity in HL-derived cell 
lines.66 Entinostat induced cell death with an IC50 of 0.4 μM. At the molecular level, 
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entinostat up-regulates p21 expression, increased H3 acetylation and down-regulates the 
anti-apoptotic X-linked inhibitor of apoptosis (XIAP) resulting in apoptosis. Moreover, the 
combination entinostat with gemcitabine or bortezomib has shown synergistic effects. Jóna 
et al found that entinostat down-regulates anti-apototic Bcl-2 and Bcl-xL expression without 
altering Mcl-1 or Bax levels and its effect was enhanced by two Bcl-2 inhibitors (ABT-737 
and obatoclax).67  
Younes et al recently presented an update of a phase II clinical study evaluating the safety 
and efficacy of entinostat as a single agent in relapsed/refractory HL.68 Interim results from 
a phase II open-label multicenter study of entinostat (ENGAGE-501) administered in an 
alternate dosing schedule (the first stage: 10 mg every 14 days, 28-day cycle; the second 
stage: 15mg every 14 days beginning C1d15) showed that of 23 patients with rel/ref HL, 
65% have disease control (CR+PR+SD). Entinostat was well tolerable with minimal AEs 
consisting of grade 1/2 fatigue, fever and GI symptoms. Serious grade 3/4 AEs were 
primarily hematological and consisted of thrombocytopenia (59.4%) and neutropenia 
(28.1%). Accrual into the study continues and the final results of this clinical trial are eagerly 
anticipated. Given the safety profile of and the long half-life of this promising agent, 
combination studies with chemotherapeutic agents based in pre-clinical studies are 
warranted to further define the role of entinostat in the management of HL. 
Givinostat (ITF-2357) is a hydroxamate pan-HDAC inhibitor with anti-inflammatory 
properties. Furlan et al reported a phase I safety and pharmacokinetics study in healthy 
males.69 They found no serious side effects and no organ toxicity. Several phase II studies of 
givinostat are in process to evaluate the safety and efficacy in rel/ref HL. A phase II open 
label non-randomized study by Viviani et al enrolled 15 patients with rel/ref disease, 13 
patients had failed HDC-ASCT, and 4 of those patients had also failed an alloSCT.70 
Givinostat was administered at a dose of 100 mg orally daily in three 4-week cycles. Seven 
of 13 patients (54%) whom completed at least one cycle of therapy were evaluable for 
response, SD was observed in 46% of the patients. Toxicity includes grade 1-2 
thrombocytopenia, leukopenia, diarrhea and/or abdominal pain; nonetheless, twenty 
percent of patients had transient drug discontinuation due to prolonged QTc. Another 
phase II study evaluated the safety and clinical activity of givinostat in combination with 
meclorethamine in patients with rel/ref HL.71 Anti-tumor activity was observed and 
correlated with a reduction in serum TARC levels. 
5.3 Targeting the PI3K/AKT/mTOR pathway in HL 
Everolimus (RAD001) binds to FK506-binding protein 12 (FKBP12) forming a complex that 
has mTOR kinase inhibition activity, inhibit tumor cell proliferation and angiogenesis by 
decreasing hypoxia-inducible factor 1a (HIF1a) expression.72,73 Everolimus demonstrated 
anti-proliferative effect in several solid tumor and hematologic malignancies including HL. 
Jundt et al showed that everolimus markedly suppress tumor cell proliferation of HL in vivo 
and down-regulates constitutively activated NFκB activity in HL cell lines.74 A phase II trial 
evaluated the clinical activity and toxicity of everolimus in patients with heavily pretreated 
rel/ref HL (median of 6 prior therapies and 84% had prior HDC-ASCS).75 Of 19 patients, one 
patient achieved CR, 8 patients achieved PR resulting in ORR of 47%, although median time 
to response was only 7.2 months.  
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Preclinical data from Georgakis et al showed temsirolimus (CCI-779) induced cell cycle 
arrest at G0/G1 phase and autophagy in HL-derived cell lines suggesting that this particular 
mTOR inhibitor may have therapeutic value in patients with HL.76 Several phase I/II trials 
studying the safety and efficacy of single agent various mTOR inhibitors (i.e. temsirolimus 
or everolimus) monotherapy, or combination with lenalidomide or sorafinib are being 
conducted to test the concept of mTOR inhibition in treatment rel/ref HL.  
5.4 Heat Shock Protein (HSP)  
Heat shock protein acting as chaperones are essential in promoting cell survival by 
maintaining the structure and function of key regulatory proteins involved in cell cycle, 
proliferation and apoptosis. HSP over-expression had been demonstrated in several 
malignancies including HL. Inhibition of HSP is another attractive target in cancer 
therapeutics. Boll et al demonstrated the biological effects of a HSP90 inhibitor, BIIB021 on 
HL-derived cell lines.77 The investigators demonstrated that, BIIB021 inhibited the 
constitutive activity of NFκB independent of IκB mutation status and increased 
susceptibility of HL cells for NK cell-mediated killing via inducing the expression of 
activating NK-cell ligands. Schoof et al showed that inhibition of HSP90 by either 
geldanamycin derivative 17-AAG or RNA interference in HL cells led to decrease cell 
proliferation and inhibition of STAT1, STAT3, STAT5, and STAT6 tyrosine phosphorylation 
possible secondary to reduced protein expression of Janus kinase (Jaks).78 HSP90 may be a 
promising target in patients with rel/ref cHL. 
6. Immune therapy for rel/ref HL 
6.1 Lenalidomide 
Lenalidomide, a novel IMiDs immunomodulatory drug is emerging as an attractive 
therapeutic option for patients with B-cell lymphoproliferative neoplasms, including HL. 
Studies in lymphoma and multiple myeloma (MM) models have demonstrated that 
lenalidomide exerts higher anti-tumor activity than thalidomide, has a unique capacity to 
enhance the innate immune system, enhance the anti-tumor activity of rituximab, and 
inhibit angiogenesis.79,80 Abnormal immune response, increased angiogenesis, and apoptosis 
resistance, which contribute to the development of HL, support the scientific standpoint of 
evaluating lenalidomide in rel/ref HL.81-83 
Lenalidomide was evaluated in patients with relapsed/refractory HL in three phase II 
clinical trials (Table 4). A phase II study presented by Böll et al and subsequently 
validated by Kuruvilla et al suggested lenalidomide had anti-tumor activity in rel/ref HL 
patients achieved a clinical response (CR or PR).84,85 More importantly, lenalidomide 
monotherapy was well tolerated and toxicities were manageable. Fehniger et al reported 
similar anti-neoplastic activity in rel/ref HL patients.86 Recently and as had been observed 
in other lenalidomide treated patients, tumor flare reaction (TFR) syndrome with sudden 
onset painful re-enlargement of tumor following early tumor shrinkage was reported in 3 
cases of relapsed HL after hematopoietic stem cell transplantation which mimic tumor 
progression but manageable with anti-inflammatory/analgesic upon continuation of 
lenalidomide.87  
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Author Agent 
Study 
Design 
(Phase) 
Patient 
population 
Clinical 
Activity 
Median 
Duration of 
Response 
Adverse Reaction 
Böll et al84 Lenalidomide N/A 
Rel/ref HL 
(N=42; 24 
evaluable pts) 
ORR 50%; 
1CR, 11 
PR 
NR 
Diarrhea, 
constipation, 
neuropathy, and 
mild dyspnea 
Kuruvilla 
et al85 
Lenalidomide II 
Rel/ref HL 
(N=15; 14 
evaluable pts) 
ORR 14%; 
2 PR 
TTP 3.2 mo. 
OS 9.1 mo 
Gr 3-4 
neutropenia, 
TCP, anemia; Gr 
2 rash 
Fehniger 
et al86 
Lenalidomide II 
Rel/ref HL 
(N=38; 36 
evaluable pts) 
ORR 19%; 
1 CR, 6 PR 
NR 
Gr 3-4 
neutropenia, 
anemia, TCP, 
(4 discontinued 
d/t rash, elevated 
billirubin) 
HL = Hodgkin Lymphoma; Rel/ref = relapsed/refractory; ORR = overall response rate; CR = complete 
response; PR = partial response; Gr = grade; TCP = thrombocytopenia; TTP= time to progression; NR = 
Not reported 
Table 4. Clinical trials evaluating lenalidomide monotherapy in relapsed/refractory 
Hodgkin lymphoma patients. 
6.2 EBV specific CTL therapy 
In general, while chemotherapy agents, small molecule inhibitors, drug immunoconjugates 
or immunodulatory drugs exhibit promising anti-tumor activity in patients with rel/ref HL, 
the duration of response to each agent when reported by investigators is rather short. 
Giving the median age of patients with rel/ref HL the incorporation of therapeutic 
strategies with durable remissions is necessary. Two therapeutic approaches are been 
actively evaluated with promising results: 1) Autologous or allogeneic LMP2-specific 
cytotoxic T-cell lymphocytes (CTL) and 2) allogeneic bone marrow transplantation.  
Approximately 30-40% of HL cases are associated with EBV infection of the HRS cells as 
proven by the expression of viral latent membrane protein (LMP).88,89 EBV is known to 
induce the surface expression of three latent antigens in EBV-infected HRS cells: LMP1, 
LMP2 and Epstein Barr nuclear antigen 1 (EBNA1). Immunotherapy targeting EBV related 
proteins in HRS cells is an area of active translational research. The generation and ex vivo 
expansion of cytotoxic T-cell lymphocytes (CTLs) specific for one or more EBV antigens had 
been studied in patients with hematological malignancies such as post-transplant 
lymphorpoliferative disorders and rel/ref HL. In general two EBV-related immunotherapy 
approached had been studied: 1) adoptive immunotherapy (administration of autologous or 
allogeneic EBV specific CTLs) and 2) vaccination of relevant epitopes from one of the EBV 
antigens to boost the patients’ own immune response.90,91   
Lucas et al demonstrated the clinical efficacy of allogeneic EBV-specific CTLs in EBV-positive 
rel/ref HL who had previously failed HDC-ASCT.92 Significant clinical activity was observed 
following allogenic CTLs infusion despite a lack to detect donor chimerism. In addition, in the 
limited number of patients evaluated the administration of fludarabine prior to CTLs infusion 
enhanced the clinical responses observed. While clinical effects had been observed in HL 
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patients treated with EBV-specific CTLs, the anti-tumor effects are not as robust as what has 
been observed in patients with PTLDs. Several observations can account for such differences, 
EBV infected HRS usually express less immunogenic EBV proteins in contrast to PTLD 
patients (LMP2). In addition, HRS cell have mechanisms to evade immune response to EBV 
infection including down-regulation of the immunogenicity of latent EBV antigen (i.e. LMP2) 
and secretion of the immunosuppressive cytokines such as IL10, IL-13, TARC, TRAFs (tumor 
necrosis factor receptor-associated factors) and TGFǃ which may suppress the efficacy of EBV 
specific CTL.93-95 Using the strategies to enhance Th1 CTLs development and decrease Th2 
cytokine production may overcome the defective immune recognition of HRS cells and 
improve the efficacy of the EBV specific CTL therapy in rel/ref HL (Table 5).   
 
Clinical trial Agent 
Study 
design 
Patient 
population 
Clinical outcome N Location 
NCT00058617 
Autologous EBV 
Specific CTLs 
Phase I 
EBV positive HL, 
NHL, Plasma 
cell neoplasm 
Safety, 
immunological 
efficacy and anti-
tumor effects 
N=18 
Baylor 
College of 
Medicine 
NCT01192464 
Autologous 
Chimeric 
Receptors CD30 
(CARCD30) + EBV 
Specific CTLs 
Phase I 
Rel CD30+ HL, 
NHL or newly 
diagnosed but 
unable to receive 
standard therapy 
CD30+ HL or 
CD30 + NHL 
with plan for 
high dose 
therapy and 
ASCT 
Safety and anti-
tumor effects of 
CARCD30 EBV 
Specific CTLs 
N=18 
Baylor 
College of 
Medicine 
NCT00082225 
Autologous/synerg
eic/allogeneic 
LMP2a Specific 
CTLs following 
anti-CD45 antibody 
Phase I 
Rel EBV positive 
HL or NHL 
Safety and anti-
tumor effects 
N=4 
Baylor 
College of 
Medicine 
NCT00062868 
Autologous/alloge
neic LMP Specific 
CTLs 
Phase I 
Rel EBV positive 
HL or NHL 
Safety and anti-
tumor effects 
N=108 
Baylor 
College of 
Medicine 
NCT00368082 
Autologous/synge
neic/ allogeneic 
TGFǃ resistant 
LMP Specific CTLs 
Phase I 
Rel EBV positive 
lymphomas 
Safety and anti-
tumor effects 
N=20 
Baylor 
College of 
Medicine 
NCT00608478 
Autologous LMP1 
and LMP2 Specific 
CTLs plus 
antiCD45 antibody 
Phase I 
Rel EBV positive 
lymphomas 
Safety and anti-
tumor effects 
N=24 
Baylor 
College of 
Medicine 
N= number of patients; HL = Hodgkin Lymphoma; NHL = Non-Hodgkin lymphoma; Rel/ref = 
relapsed/refractory; EBV = Epstein Barr Virus; CTL = cytotoxic T-cell lymphocytes; LMP = Latent 
membrane protein;  LMP2a = Latent membrane protein 2a.  
Table 5. Ongoing trials of EBV-Specific CTLs for patients with relapsed/refractory Hodgkin 
lymphoma. 
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6.3 Allogeneic bone marrow transplant (AlloSCT) 
Approximately 50% of patients with relapsed Hodgkin lymphoma who undergo HDC-
ASCT relapse as a consequence of refractory disease, usually within the first year post-
transplant.96,97 Relapsed HL patients after HDC-ASCT have a poor clinical outcome and 
represent a therapeutic challenge for the practicing oncologist. There are several proposed 
risk factors to identify patients at high risk to develop disease progression following HDC-
ASCT such as chemotherapy resistant disease prior to HDC-ASCT, B symptoms at the time 
of relapse, residual disease at the time of transplantation by functional imaging, extra-nodal 
disease at the time of relapse, and bulky disease.98,99 Patients with any of these high risk 
factors may be suited for alternative therapeutic strategies such as tandem transplant, 
allogeneic bone marrow transplant, and/or post-HDC-ASCT maintenance therapy in the 
context of a clinical trial.  
A second HDC-ASCT could be considered for patients with a long period of remission 
following the initial transplant (>3 years) or those whom alloSCT is not feasible.100   
AlloSCT has been used in patients with rel/ref HL with controversial results. Often the high 
incidence of transplant related mortality (TRM) offsets the potential clinical benefit.101 While 
the incorporation of reduced intensity conditioning regimens has been associated with 
lower TRM rates, the long-term PFS rates rarely exceed 20-25% questioning the validity of 
this approach. Patients who have chemotherapy sensitive disease, non-bulky disease, and 
have greater than 1 year of remission after the first HDC-ASCT seem to have most benefited 
with this approach.102  
Despite early good responses, the results of RIC-AlloSCT demonstrate a disappointing 
clinical outcome and lack of long term disease control with 2 year OS of 29-66% and 2 year 
PFS of 20-39% regardless of conditioning regimens or donor types.103-105 Peggs et al reported 
durable response to donor lymphocyte infusion (DLI) in patients with relapsed HL post 
alloSCT that incorporated in vivo T-cell depletion.106 DLI was administered to 46 patients for 
mixed chimerism (n=22) and relapsed disease post-alloSCT (n=24). Eighty-six percent of 
patients with mixed chimerism converted to full donor status and had a 4-year relapse 
incidence of 5%. More importantly, CR and PR were noted in 58.3% and 20.8% of 24 patients 
with relapsed disease respectively, suggesting the existence of graft vs. HL effects. Ongoing 
clinical studies are investigating the role of alloSCT in relapsed HL patients with poor-risk 
features who are at high risk to relapse after HDC-ASCT.  
In summary, promising therapies are emerging for the treatment of rel/ref HL. Substantial 
and occasionally durable remissions have been observed with some therapeutic 
interventions, such as HDACi, drug immunoconjugates, and cellular therapy. Ongoing 
studies will hopefully guide the integration of these therapies in the current treatment of 
high-risk HL in an attempt to improve cure rates. In addition, ongoing scientific and 
translational research and the importance of the development of novel therapeutics for 
patients with ref/rel HL should not be underemphasized. 
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